Armando Stabile1, Elio Mazzone2, Giuseppe O Cirulli2, Francesco De Cobelli3, Jeremy Grummet4, Harriet C Thoeny5, Mark Emberton6, Morgan Pokorny7, Peter A Pinto8, Samir S Taneja9. 1. Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: armando.stabile88@gmail.com. 2. Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy. 3. Department of Radiology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy. 4. Department of Surgery, Central Clinical School, Monash University, Melbourne, Australia. 5. Department of Radiology, Hôpital Cantonal de Fribourg HFR, University of Fribourg, Fribourg, Switzerland. 6. UCL Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK. 7. Department of Urology, Auckland City Hospital, Auckland, New Zealand. 8. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 9. Department of Urologic Oncology, NYU Langone Medical Center, New York, NY, USA.
Abstract
CONTEXT: The diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) for prostate cancer (PCa) diagnosis has been extensively explored. Little is known about the prognostic value of mpMRI suspicion scores and other quantitative mpMRI information. OBJECTIVE: To systematically review the current literature assessing the relationship between pretreatment mpMRI and oncological outcomes after primary treatment for PCa to assess the role of mpMRI as a prognostic tool. EVIDENCE ACQUISITION: A computerized bibliographic search of MEDLINE/PubMed, EMBASE, Scopus, and the Cochrane Library CENTRAL databases was performed for all studies assessing the relationship between mpMRI and oncological outcomes after primary treatment for PCa. The review protocol is registered in the PROSPERO database (CRD42020209899). EVIDENCE SYNTHESIS: A total of six studies were included. Reliable evidence is still limited in this field. The Prostate Imaging-Reporting and Data System (PI-RADS) score was an independent predictor of biochemical recurrence (BCR) after radical prostatectomy (RP) in the majority of the studies included. The tumor volume at mpMRI was not significantly associated with BCR after RP for PCa. Data on disease progression and PCa-specific mortality are limited. Heterogeneity among the studies was substantial. CONCLUSIONS: The review shows that PI-RADS scores provide information on the future likelihood of cancer recurrence or progression, at least for men undergoing RP. We are of the view that this information should be taken into account to identify men at higher risk of unfavorable outcomes. PATIENT SUMMARY: A higher Prostate Imaging-Reporting and Data System score for magnetic resonance imaging of the prostate seems to be positively associated with oncological failure in prostate cancer and should be incorporated into future risk models.
CONTEXT: The diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) for prostate cancer (PCa) diagnosis has been extensively explored. Little is known about the prognostic value of mpMRI suspicion scores and other quantitative mpMRI information. OBJECTIVE: To systematically review the current literature assessing the relationship between pretreatment mpMRI and oncological outcomes after primary treatment for PCa to assess the role of mpMRI as a prognostic tool. EVIDENCE ACQUISITION: A computerized bibliographic search of MEDLINE/PubMed, EMBASE, Scopus, and the Cochrane Library CENTRAL databases was performed for all studies assessing the relationship between mpMRI and oncological outcomes after primary treatment for PCa. The review protocol is registered in the PROSPERO database (CRD42020209899). EVIDENCE SYNTHESIS: A total of six studies were included. Reliable evidence is still limited in this field. The Prostate Imaging-Reporting and Data System (PI-RADS) score was an independent predictor of biochemical recurrence (BCR) after radical prostatectomy (RP) in the majority of the studies included. The tumor volume at mpMRI was not significantly associated with BCR after RP for PCa. Data on disease progression and PCa-specific mortality are limited. Heterogeneity among the studies was substantial. CONCLUSIONS: The review shows that PI-RADS scores provide information on the future likelihood of cancer recurrence or progression, at least for men undergoing RP. We are of the view that this information should be taken into account to identify men at higher risk of unfavorable outcomes. PATIENT SUMMARY: A higher Prostate Imaging-Reporting and Data System score for magnetic resonance imaging of the prostate seems to be positively associated with oncological failure in prostate cancer and should be incorporated into future risk models.
Authors: Francesco Barletta; Elio Mazzone; Armando Stabile; Simone Scuderi; Giorgio Brembilla; Mario de Angelis; Giuseppe Ottone Cirulli; Vito Cucchiara; Giorgio Gandaglia; R Jeffrey Karnes; Morgan Roupret; Francesco De Cobelli; Francesco Montorsi; Alberto Briganti Journal: World J Urol Date: 2022-09-23 Impact factor: 3.661
Authors: Dominik Deniffel; Nathan Perlis; Sangeet Ghai; Stephanie Girgis; Gerard M Healy; Neil Fleshner; Robert Hamilton; Girish Kulkarni; Ants Toi; Theodorus van der Kwast; Alexandre Zlotta; Antonio Finelli; Masoom A Haider Journal: Eur Radiol Date: 2022-05-04 Impact factor: 7.034
Authors: Artitaya Lophatananon; Matthew H V Byrne; Tristan Barrett; Anne Warren; Kenneth Muir; Ibifuro Dokubo; Fanos Georgiades; Mostafa Sheba; Lisa Bibby; Vincent J Gnanapragasam Journal: BMC Cancer Date: 2022-08-11 Impact factor: 4.638
Authors: Joseph M Norris; Lucy A M Simmons; Abi Kanthabalan; Alex Freeman; Neil McCartan; Caroline M Moore; Shonit Punwani; Hayley C Whitaker; Mark Emberton; Hashim U Ahmed Journal: Eur Urol Open Sci Date: 2021-06-15